HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ODS Office Relocation Meant To Accommodate Staffing Increase

This article was originally published in The Tan Sheet

Executive Summary

NIH's Office of Dietary Supplements is moving to a new location due to increased staff size and anticipated continued growth

You may also be interested in...



ODS new address

NIH's Office of Dietary Supplements' move has been completed (1"The Tan Sheet, June 10, 2002, p. 8); the new address is National Institutes of Health, 6100 Executive Blvd., Room 3B01, MSC 7517, Bethesda, Md., 20892...

ODS Elevation To NIH Center Suggested By CRN Rep

The possibility of shifting dietary supplement research out of the National Center for Complementary & Alternative Medicine and into the Office of Dietary Supplements is "a political decision that needs to be revisited," according to CRN President & CEO John Cordaro

Labor/HHS appropriations

Conference report urges HHS secretary "to form a coordinating unit to review" White House CAM Commission report and "implement ways to better coordinate the department's many CAM-related activities." Conferees also urge secretary "to work with FDA and ODS to resolve [ephedra] rulemaking expeditiously." Appropriations bill, passed by Congress before the holiday recess, provides $17 mil. to ODS (up 70% from FY 2001), $104.6 mil. to NCCAM (up 17.3%) (1"The Tan Sheet" Dec. 24, 2001, In Brief). Conference report also calls for publication of dietary supplement GMPs within 15 days of bill's enactment; however, FDA withdrew GMPs proposed rule from OMB Dec. 19...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel